Phase 1 Renal Impairment Clinical Trials

12 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Phase 1 Renal Impairment Clinical Trials

What is a Phase 1 trial?

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function

Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)

Effect of Renal Impairment on Enpatoran Pharmacokinetics

Clofutriben Pharmacokinetics in Patients With Impaired Renal Function

A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls

Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control Participants

Study in Participants With Normal Kidney Function and Reduced Kidney Function to Test How Kidney Function Can Change What Happens to Obeldesivir in the Body

Effect of ONC201 on participants with renal impairment

A study comparing how fast the trial drug RVX000222 is cleared from the body, in healthy adults and in adults with severely reduced kidney function.

Study to find out if the drug “Vessel Dilator” is absorbed from an infusion under the skin and is safe and tolerated and improves heart function in people diagnosed with stable congestive heart failure and a moderate degree of kidney function loss.

Study to find out if the drug “Vessel Dilator” is absorbed from an injection under the skin and, whether it improves heart function in people diagnosed with chronic heart failure and a moderate degree of kidney function loss.